|
|
Article: Alexion Initiates Phase II Efficacy Study of C5 Complement Inhibitor in Rheumatoid Arthritis Patients.
- Article from:
- PR Newswire
- Article date:
- August 4, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW HAVEN, Conn., Aug. 4 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has initiated a Phase II efficacy trial with its anti-inflammatory complement inhibitor drug candidate 5G1.1 in rheumatoid arthritis patients. The Phase II multi-center, double-blinded, randomized, placebo-controlled study is expected to examine the safety and clinical efficacy of repeated dosing of 5G1.1 in approximately 200 rheumatoid arthritis patients in the United States. This efficacy study follows clinical results announced in April of this year in which a single administration of 5G1.1 in this patient population was associated with a significant reduction ...